Raras
Buscar doenças, sintomas, genes...
Encefalopatia epiléptica e do desenvolvimento infantil precoce
ORPHA:1934CID-10 · G40.3CID-11 · 8A62.YDOENÇA RARA

Uma síndrome de epilepsia que afeta recém-nascidos e bebês pequenos, caracterizada por crises epilépticas (convulsões) frequentes e difíceis de controlar com medicamentos, que começam antes ou até os 3 meses de idade. O eletroencefalograma (EEG) mostra alterações mesmo fora das crises, e o exame neurológico também apresenta resultados incomuns. Em até 80% dos casos, a EIDEE é causada por um problema de base, seja ele estrutural (no formato ou estrutura do cérebro), genético (ligado aos genes) ou metabólico (relacionado ao funcionamento do organismo).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma síndrome de epilepsia que afeta recém-nascidos e bebês pequenos, caracterizada por crises epilépticas (convulsões) frequentes e difíceis de controlar com medicamentos, que começam antes ou até os 3 meses de idade. O eletroencefalograma (EEG) mostra alterações mesmo fora das crises, e o exame neurológico também apresenta resultados incomuns. Em até 80% dos casos, a EIDEE é causada por um problema de base, seja ele estrutural (no formato ou estrutura do cérebro), genético (ligado aos genes) ou metabólico (relacionado ao funcionamento do organismo).

Publicações científicas
30 artigos
Último publicado: 2026 Feb 25

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G40.3
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
38 sintomas
🦴
Ossos e articulações
6 sintomas
😀
Face
3 sintomas
💪
Músculos
3 sintomas
📏
Crescimento
3 sintomas
👁️
Olhos
2 sintomas

+ 26 sintomas em outras categorias

Características mais comuns

100%prev.
Convulsão
90%prev.
Crise mioclônica generalizada
Muito frequente (99-80%)
90%prev.
Encefalopatia epiléptica
Muito frequente (99-80%)
90%prev.
Deficiência intelectual
Muito frequente (99-80%)
90%prev.
Crise motora focal
Muito frequente (99-80%)
90%prev.
Atraso global do desenvolvimento
Muito frequente (99-80%)
90sintomas
Muito frequente (6)
Frequente (13)
Ocasional (26)
Muito raro (18)
Sem dados (27)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 90 características clínicas mais associadas, ordenadas por frequência.

ConvulsãoSeizure
Muito frequente100%
Crise mioclônica generalizadaGeneralized myoclonic seizure
Muito frequente (99-80%)90%
Encefalopatia epilépticaEpileptic encephalopathy
Muito frequente (99-80%)90%
Deficiência intelectualIntellectual disability
Muito frequente (99-80%)90%
Crise motora focalFocal motor seizure
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico30PubMed
Últimos 10 anos30publicações
Pico20249 papers
Linha do tempo
2026Hoje · 2026🧪 2010Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

21 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, Not applicable, X-linked recessive.

GRIN1Glutamate receptor ionotropic, NMDA 1Disease-causing germline mutation(s) (loss of function) inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:21376300, PubMed:26875626, PubMed:26919761, PubMed:28126851, PubMed:28228639, PubMed:36959261, PubMed:7679115, PubMed:7681588, PubMed:7685113). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the long-term potentiation (LTP) (PubMed:26875626). Channel

LOCALIZAÇÃO

Cell membranePostsynaptic cell membranePostsynaptic density membraneSynaptic cell membrane

VIAS BIOLÓGICAS (9)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant

An autosomal dominant neurodevelopmental disorder characterized by severe intellectual disability and developmental delay, absent speech, muscular hypotonia, dyskinesia, and hyperkinetic movements. Cortical blindness, cerebral atrophy, and seizures are present in some patients.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
222.8 TPM
Cerebelo
219.9 TPM
Brain Frontal Cortex BA9
191.7 TPM
Cérebro - Hemisfério cerebelar
171.8 TPM
Brain Nucleus accumbens basal ganglia
119.2 TPM
OUTRAS DOENÇAS (7)
neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominantneurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessivedevelopmental and epileptic encephalopathy 101early-infantile DEE
HGNC:4584UniProt:Q05586
SLC1A2Excitatory amino acid transporter 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:14506254, PubMed:15265858, PubMed:26690923, PubMed:7521911). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion (PubMed:14506254). Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Astrocytic Glutamate-Glutamine Uptake And MetabolismGlutamate Neurotransmitter Release CycleSLC-mediated transport of amino acids
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 41

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE41 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Caudate basal ganglia
460.3 TPM
Brain Putamen basal ganglia
378.3 TPM
Brain Anterior cingulate cortex BA24
377.3 TPM
Brain Nucleus accumbens basal ganglia
373.1 TPM
Córtex cerebral
361.7 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 41undetermined early-onset epileptic encephalopathy
HGNC:10940UniProt:P43004
PNKPBifunctional polynucleotide phosphatase/kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways (PubMed:10446192, PubMed:10446193, PubMed:15385968, PubMed:20852255, PubMed:28453785). Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone (PubMed:10446192, PubMed:10446

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (1)
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
MECANISMO DE DOENÇA

Microcephaly, seizures, and developmental delay

An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
66.8 TPM
Tireoide
63.9 TPM
Baço
59.2 TPM
Glândula adrenal
55.9 TPM
Cervix Endocervix
51.8 TPM
OUTRAS DOENÇAS (4)
microcephaly, seizures, and developmental delayataxia - oculomotor apraxia type 4Charcot-Marie-Tooth disease type 2B2early-infantile DEE
HGNC:9154UniProt:Q96T60
GRM7Metabotropic glutamate receptor 7Disease-causing germline mutation(s) inRestrito
FUNÇÃO

G-protein coupled receptor activated by glutamate that regulates axon outgrowth through the MAPK-cAMP-PKA signaling pathway during neuronal development (PubMed:33500274). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase that it inhibits (PubMed:9473604)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (i) signalling eventsClass C/3 (Metabotropic glutamate/pheromone receptors)
MECANISMO DE DOENÇA

Neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities

An autosomal recessive neurodevelopmental disorder characterized by global developmental delay, hypotonia, severe to profound intellectual disability, early-onset epilepsy, and microcephaly. Neuroimaging shows cerebral atrophy, thin corpus callosum and hypomyelination in a majority of cases. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Frontal Cortex BA9
4.9 TPM
Hipotálamo
3.7 TPM
Córtex cerebral
3.1 TPM
Brain Nucleus accumbens basal ganglia
2.7 TPM
Brain Anterior cingulate cortex BA24
2.6 TPM
OUTRAS DOENÇAS (3)
neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalitiesearly-infantile DEEautosomal recessive non-syndromic intellectual disability
HGNC:4599UniProt:Q14831
KCNA1Potassium voltage-gated channel subfamily A member 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818, PubMed:8845167). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alte

LOCALIZAÇÃO

Cell membraneMembraneCell projection, axonCytoplasmic vesiclePerikaryonEndoplasmic reticulumCell projection, dendriteCell junctionSynapsePresynaptic cell membranePresynapse

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Episodic ataxia 1

An autosomal dominant disorder characterized by brief episodes of ataxia and dysarthria. Neurological examination during and between the attacks demonstrates spontaneous, repetitive discharges in the distal musculature (myokymia) that arise from peripheral nerve. Nystagmus is absent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
56.0 TPM
Cerebelo
42.4 TPM
Brain Frontal Cortex BA9
13.3 TPM
Brain Nucleus accumbens basal ganglia
7.8 TPM
Brain Caudate basal ganglia
7.8 TPM
OUTRAS DOENÇAS (5)
episodic ataxia type 1early-infantile DEEepisodic kinesigenic dyskinesiahereditary continuous muscle fiber activity
HGNC:6218UniProt:Q09470
SCN1BSodium channel regulatory subunit beta-1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Regulatory subunit of multiple voltage-gated sodium (Nav) channels directly mediating the depolarization of excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na+ ions provoke

LOCALIZAÇÃO

Cell membranePerikaryonCell projectionCell projection, axonSecreted

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Generalized epilepsy with febrile seizures plus 1

A rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. This disease combines febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
166.3 TPM
Cérebro - Hemisfério cerebelar
165.4 TPM
Músculo esquelético
108.1 TPM
Brain Frontal Cortex BA9
81.3 TPM
Córtex cerebral
67.1 TPM
OUTRAS DOENÇAS (11)
generalized epilepsy with febrile seizures plus, type 1developmental and epileptic encephalopathy, 52Brugada syndrome 5atrial fibrillation, familial, 13
HGNC:10586UniProt:Q07699
ARXHomeobox protein ARXDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor (PubMed:22194193, PubMed:31691806). Binds to specific sequence motif 5'-TAATTA-3' in regulatory elements of target genes, such as histone demethylase KDM5C (PubMed:22194193, PubMed:31691806). Positively modulates transcription of KDM5C (PubMed:31691806). Activates expression of KDM5C synergistically with histone lysine demethylase PHF8 and perhaps in competition with transcription regulator ZNF711; synergy may be related to enrichment of histone H3K4me3 in regulatory element

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Lissencephaly, X-linked 2

A classic type lissencephaly associated with abnormal genitalia. Patients have severe congenital or postnatal microcephaly, lissencephaly, agenesis of the corpus callosum, neonatal-onset intractable epilepsy, poor temperature regulation, chronic diarrhea, and ambiguous or underdeveloped genitalia.

OUTRAS DOENÇAS (9)
X-linked lissencephaly with abnormal genitaliaPartington syndromecorpus callosum agenesis-abnormal genitalia syndromedevelopmental and epileptic encephalopathy, 1
HGNC:18060UniProt:Q96QS3
SLC25A22Mitochondrial glutamate carrier 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial glutamate/H(+) symporter. Responsible for the transport of glutamate from the cytosol into the mitochondrial matrix with the concomitant import of a proton (PubMed:11897791). Plays a role in the control of glucose-stimulated insulin secretion (By similarity)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
SLC-mediated transport of neurotransmittersMalate-aspartate shuttle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 3

A severe form of epilepsy characterized by frequent tonic seizures or spasms beginning in infancy with a specific EEG finding of suppression-burst patterns, characterized by high-voltage bursts alternating with almost flat suppression phases. DEE3 is characterized by a very early onset, erratic and fragmentary myoclonus, massive myoclonus, partial motor seizures and late tonic spasms. The prognosis is poor, with no effective treatment, and children with the condition either die within 1 to 2 years after birth or survive in a persistent vegetative state.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
172.4 TPM
Cérebro - Hemisfério cerebelar
161.2 TPM
Brain Frontal Cortex BA9
119.4 TPM
Córtex cerebral
112.9 TPM
Brain Anterior cingulate cortex BA24
111.3 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 3malignant migrating partial seizures of infancyearly-infantile DEE
HGNC:19954UniProt:Q9H936
RHOBTB2Rho-related BTB domain-containing protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulator of cell proliferation and apoptosis (PubMed:21801820). It likely functions as a substrate-adapter that recruits key substrates, e.g. MSI2, to CUL3-based ubiquitin ligase complexes for degradation (PubMed:15107402, PubMed:27941885). Required for MSI2 ubiquitination and degradation (PubMed:27941885)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
RHOBTB2 GTPase cycle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 64

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE64 is an autosomal dominant form characterized by onset of seizures usually in the first year of life. Seizure types are variable and include focal dyscognitive and generalized tonic-clonic seizures, as well as febrile seizures in the mildest affected individuals. Seizures tend to respond to medical treatment.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
75.6 TPM
Córtex cerebral
63.2 TPM
Brain Frontal Cortex BA9
60.2 TPM
Brain Caudate basal ganglia
54.5 TPM
Brain Putamen basal ganglia
40.2 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 64alternating hemiplegia of childhoodearly-infantile DEE
HGNC:18756UniProt:Q9BYZ6
PIGQPhosphatidylinositol N-acetylglucosaminyltransferase subunit QDisease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 4

An autosomal recessive syndrome characterized by onset of refractory seizures in the first months of life. Additional clinical features include severe global developmental delay, dysmorphic facial features, and skeletal, renal and ophthalmic anomalies. At the cellular level, the disorder is caused by a defect in the synthesis of glycosylphosphatidylinositol (GPI).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
53.0 TPM
Testículo
49.5 TPM
Pituitária
41.1 TPM
Rim - Medula
33.3 TPM
Cerebelo
31.1 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 77early-infantile DEE
HGNC:14135UniProt:Q9BRB3
CASKKappa-caseinDisease-causing germline mutation(s) (loss of function) inAltamente restrito
FUNÇÃO

Kappa-casein stabilizes micelle formation, preventing casein precipitation in milk

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (7)
Assembly and cell surface presentation of NMDA receptorsDopamine Neurotransmitter Release CycleNeurexins and neuroliginsNephrin family interactionsSyndecan interactions
OUTRAS DOENÇAS (4)
FG syndrome 4syndromic X-linked intellectual disability Najm typeearly-infantile DEEnon-syndromic X-linked intellectual disability
HGNC:1497UniProt:P07498
SIK1Serine/threonine-protein kinase SIK1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression. Phosphorylates HDAC4, HDAC5, PPME1, SREBF1, CRTC1/TORC1. Inhibits CREB activity by phosphorylating and inhibiting activity of TORCs, the CREB-specific coactivators, like CRTC2/TORC2 and CRTC3/TORC3 in response to cAMP signaling (PubMed:29211348). Acts as a tumor suppressor and plays a key role in p53/TP53

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 30

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Not Sun Exposed Suprapubic
14.4 TPM
Skin Sun Exposed Lower leg
10.9 TPM
Ovário
4.6 TPM
Fallopian Tube
4.2 TPM
Tecido adiposo
3.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 30early-infantile DEE
HGNC:11142UniProt:P57059
CDKL5Cyclin-dependent kinase-like 5Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates phosphorylation of MECP2 (PubMed:15917271, PubMed:16935860). May regulate ciliogenesis (PubMed:29420175)

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, cilium basal bodyCytoplasm, cytoskeleton, microtubule organizing center, centrosome

OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 2X-linked retinoschisisCDKL5 disorderearly-infantile DEE
HGNC:11411UniProt:O76039
GNAO1Guanine nucleotide-binding protein G(o) subunit alphaDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:29925951, PubMed:33408414). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound

LOCALIZAÇÃO

Cell membraneMembrane

VIAS BIOLÓGICAS (1)
Ca2+ pathway
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 17

A severe neurologic disorder characterized by onset of intractable seizures in the first weeks or months of life and usually associated with EEG abnormalities. Affected infants have very poor psychomotor development and may have brain abnormalities, such as cerebral atrophy or thin corpus callosum. Some patients may show involuntary movements.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
92.1 TPM
Cérebro - Hemisfério cerebelar
82.9 TPM
Brain Frontal Cortex BA9
82.9 TPM
Córtex cerebral
79.5 TPM
Brain Caudate basal ganglia
74.3 TPM
OUTRAS DOENÇAS (4)
neurodevelopmental disorder with involuntary movementsdevelopmental and epileptic encephalopathy, 17GNAO1-related developmental delay-seizures-movement disorder spectrumearly-infantile DEE
HGNC:4389UniProt:P09471
TRIM8E3 ubiquitin-protein ligase TRIM8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

E3 ubiquitin-protein ligase that participates in multiple biological processes including cell survival, differentiation, apoptosis, and in particular, the innate immune response (PubMed:27981609, PubMed:28747347). Participates in the activation of interferon-gamma signaling by promoting proteasomal degradation of the repressor SOCS1 (PubMed:12163497). Plays a positive role in the TNFalpha and IL-1beta signaling pathways. Mechanistically, induces the 'Lys-63'-linked polyubiquitination of MAP3K7/T

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nuclear body

VIAS BIOLÓGICAS (1)
Interferon gamma signaling
MECANISMO DE DOENÇA

Focal segmental glomerulosclerosis and neurodevelopmental syndrome

An autosomal dominant disorder characterized by global developmental delay associated with variable features of focal segmental glomerulosclerosis, a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Some patients have transient proteinuria and others require renal transplant. Neurodevelopmental features are also variable, with some patients having only mildly impaired intellectual development, and others having a severe developmental disorder associated with early-onset refractory seizures or epileptic encephalopathy. Additional features, including feeding difficulties, poor overall growth, and non-specific dysmorphic facial features, are commonly observed.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
178.8 TPM
Cervix Endocervix
158.3 TPM
Tireoide
154.4 TPM
Tecido adiposo
150.5 TPM
Aorta
149.7 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
focal segmental glomerulosclerosis and neurodevelopmental syndromeearly-infantile DEE
HGNC:15579UniProt:Q9BZR9
CACNA1EVoltage-dependent R-type calcium channel subunit alpha-1EDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells (PubMed:30343943). They are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel. They are however insensit

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (2)
Presynaptic depolarization and calcium channel openingRegulation of insulin secretion
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 69

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE69 is an autosomal dominant form characterized by refractory seizures, hypotonia, and profoundly impaired development often associated with macrocephaly, hyperkinetic movements, and contractures. The disorder can sometimes result in early death. Some patients may have a favorable seizure response to topiramate medication.

OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 69early-infantile DEE
HGNC:1392UniProt:Q15878
SCN2ASodium channel protein type 2 subunit alphaDisease-causing germline mutation(s) (gain of function) inAltamente restrito
FUNÇÃO

Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient (PubMed:1325650, PubMed:17021166, PubMed:28256214, PubMed:29844171). Implicated in the regulation of hippocampal replay occurring within sharp wave ripples (SPW-R) important for memory (By simi

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Seizures, benign familial infantile, 3

A form of benign familial infantile epilepsy, a neurologic disorder characterized by afebrile seizures occurring in clusters during the first year of life, without neurologic sequelae. BFIS3 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
70.3 TPM
Cerebelo
65.2 TPM
Brain Frontal Cortex BA9
19.3 TPM
Córtex cerebral
11.5 TPM
Brain Nucleus accumbens basal ganglia
9.1 TPM
OUTRAS DOENÇAS (10)
seizures, benign familial infantile, 3episodic ataxia, type 9developmental and epileptic encephalopathy, 11complex neurodevelopmental disorder
HGNC:10588UniProt:Q99250
DMXL2DmX-like protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May serve as a scaffold protein for MADD and RAB3GA on synaptic vesicles (PubMed:11809763). Plays a role in the brain as a key controller of neuronal and endocrine homeostatic processes (By similarity)

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle

MECANISMO DE DOENÇA

Polyendocrine-polyneuropathy syndrome

A progressive endocrine and neurodevelopmental disorder manifesting early in childhood with growth retardation and recurrent episodes of profound asymptomatic hypoglycemia. PEPNS is characterized by central hypothyroidism, hypogonadotropic hypogonadism, incomplete puberty, progressive non-autoimmune insulin-dependent diabetes mellitus, peripheral demyelinating sensorimotor polyneuropathy, and cerebellar and pyramidal signs.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
22.0 TPM
Cerebelo
20.8 TPM
Pituitária
16.6 TPM
Pulmão
14.8 TPM
Testículo
13.9 TPM
OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 81polyendocrine-polyneuropathy syndromehearing loss, autosomal dominant 71early-infantile DEE
HGNC:2938UniProt:Q8TDJ6
NEUROD2Neurogenic differentiation factor 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcriptional regulator implicated in neuronal determination. Mediates calcium-dependent transcription activation by binding to E box-containing promoter. Critical factor essential for the repression of the genetic program for neuronal differentiation; prevents the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Induces transcription of ZEB1, which in turn represses neuronal differentiation by down-regulating REST expression. Plays a

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 72

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE72 is an autosomal dominant form with variable severity and onset in infancy.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
192.0 TPM
Cerebelo
174.4 TPM
Brain Frontal Cortex BA9
40.4 TPM
Córtex cerebral
32.4 TPM
Brain Anterior cingulate cortex BA24
27.8 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 72early-infantile DEE
HGNC:7763UniProt:Q15784
SLC32A1Vesicular inhibitory amino acid transporterDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Antiporter that exchanges vesicular protons for cytosolic 4-aminobutanoate or to a lesser extend glycine, thus allowing their secretion from nerve terminals. The transport is equally dependent on the chemical and electrical components of the proton gradient (By similarity). May also transport beta-alanine (By similarity). Acidification of GABAergic synaptic vesicles is a prerequisite for 4-aminobutanoate uptake (By similarity)

LOCALIZAÇÃO

Cytoplasmic vesicle membranePresynapse

VIAS BIOLÓGICAS (1)
GABA synthesis, release, reuptake and degradation
MECANISMO DE DOENÇA

Generalized epilepsy with febrile seizures plus 12

An autosomal dominant neurologic disorder with variable expressivity and incomplete penetrance. Affected individuals have variable types of seizures, most often febrile seizures, sometimes combined with non-febrile focal or generalized seizures. Rarely, afebrile tonic-clonic seizures have been observed.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Nucleus accumbens basal ganglia
51.3 TPM
Brain Caudate basal ganglia
26.5 TPM
Hipotálamo
16.1 TPM
Cerebelo
15.7 TPM
Brain Putamen basal ganglia
15.7 TPM
OUTRAS DOENÇAS (4)
generalized epilepsy with febrile seizures plus, type 12developmental and epileptic encephalopathy 114early-infantile DEEgeneralized epilepsy with febrile seizures plus
HGNC:11018UniProt:Q9H598
PIGPPhosphatidylinositol N-acetylglucosaminyltransferase subunit PDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 55

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE55 is an autosomal recessive condition.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
8.1 TPM
Testículo
7.4 TPM
Brain Spinal cord cervical c-1
7.3 TPM
Glândula adrenal
6.9 TPM
Nervo tibial
6.4 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 55early-infantile DEE
HGNC:3046UniProt:P57054

Variantes genéticas (ClinVar)

756 variantes patogênicas registradas no ClinVar.

🧬 GRIN1: NM_007327.4(GRIN1):c.931A>G (p.Asn311Asp) ()
🧬 GRIN1: NM_007327.4(GRIN1):c.790G>A (p.Asp264Asn) ()
🧬 GRIN1: NM_007327.4(GRIN1):c.640del (p.Leu214fs) ()
🧬 GRIN1: NM_007327.4(GRIN1):c.1139T>C (p.Ile380Thr) ()
🧬 GRIN1: GRCh38/hg38 9q34.3(chr9:135445565-138172039)x1 ()
Ver todas no ClinVar

Vias biológicas (Reactome)

35 vias biológicas associadas aos genes desta condição.

EPHB-mediated forward signaling Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation Astrocytic Glutamate-Glutamine Uptake And Metabolism Glutamate Neurotransmitter Release Cycle SLC-mediated transport of amino acids APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Voltage gated Potassium channels Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Sensory perception of sweet, bitter, and umami (glutamate) taste SLIT2 gene expression is stimulated by ISL1 Primary multipotent pancreatic progenitor cell produces trunk bipotent pancreatic progenitor cell SLC-mediated transport of neurotransmitters Malate-aspartate shuttle RHOBTB2 GTPase cycle Synthesis of glycosylphosphatidylinositol (GPI) Miscellaneous transport and binding events Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes Transcriptional Regulation by MECP2 Loss of function of MECP2 in Rett syndrome Regulation of MECP2 expression and activity Ca2+ pathway Interferon gamma signaling Presynaptic depolarization and calcium channel opening Regulation of insulin secretion GABA synthesis, release, reuptake and degradation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
1Fase 11
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Encefalopatia epiléptica e do desenvolvimento infantil precoce

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Revisão sistemática
Timeline de publicações
30 papers (10 anos)
#1

Functional Characterization of a De Novo SCN2A Mixed Variant Linked to Early Infantile Developmental and Epileptic Encephalopathy.

Neurology. Genetics2026 Feb

Pathogenic variants in the SCN2A gene, encoding the α-subunit type 2 of the voltage-gated sodium channel NaV1.2, cause a phenotypic spectrum including 4 major disorders as benign familial infantile seizures, developmental and epileptic encephalopathy, intellectual disability, and autism. Gain-of-function variants resulting phenotypes may be treated with sodium channel blockers, while loss-of-function (LoF) conditions are non-respondent. We focused on the effects of the pathogenic SCN2A variant c.4976C>T (p.A1659V) found in heterozygosity in 3 patients affected by DEE non responsive to SCB. We functionally investigated this previously uncharacterized SCN2A variant. Three individuals with the SCN2A c.4976C>T (p.A1659V) variant were studied. This variant was detected by next-generation sequencing (NGS). The nucleotide substitution was inserted by site-directed mutagenesis in a stabilized SCN2A plasmid encoding NaV1.2. Expression and functional characterization of the NaV1.2 A1659V variant was performed in HEK293 cells by western blotting, confocal microscopy, and patch clamp electrophysiology. The same de novo pathogenic SCN2A variant was detected in 3 patients with DEE characterized by early onset, severe ID, and seizures unresponsive to SCB. In 2 patients, the variant is in a mosaic state. The NaV1.2 A1659V variant did not affect channel protein expression while exhibiting significant effects on its function as shown by the reduced Na+ currents, a shift of the activation curve toward more negative potentials, a shift of the inactivation curve to more negative voltages, and slower kinetics of inactivation compared with native NaV1.2 in HEK293 cells. Simulations suggested that the variant increases excitability in neurons. These results revealed the multifaceted functional effect of A1659V variant on channel activity and highlighted the complex genotype-phenotype correlation underlying significant clinical and pharmacological variability in SCN2A-related encephalopathies.

#2

Long-Read Genome Sequencing Establishes Biallelic Pathogenic Variants in DNM1 With Distinct Functional Effects as the Cause of Early Infantile Developmental and Epileptic Encephalopathy.

American journal of medical genetics. Part A2026 Apr

Heterozygous de novo and inherited biallelic pathogenic variants in DNM1 have been reported in association with autosomal dominant (AD) and autosomal recessive (AR) developmental and epileptic encephalopathy, respectively, due to aberrant dynamin function or expression, with each inheritance pattern associated with a different mechanism of disease. We report an instance of DNM1-related early infantile developmental and epileptic encephalopathy due to compound heterozygous pathogenic variants with different functional effects: the de novo dominant negative-associated c.194C>A (p.Thr65Asn), and the maternally inherited loss of function-associated c.850C>T (p.Gln284*). We describe this patient's severe clinical presentation and disease progression as compared to those previously reported with either AD or AR DNM1-related disease. We hypothesize about the interactions and outcomes of the two variants at the molecular level following review of in vitro and in vivo functional data and demonstrate the utility of long-read genome sequencing for phasing the variants and confirming this individual's molecular diagnosis.

#3

Kcnq2 R213 knock-in mice reveal variant- and region-specific mechanisms underlying self-limited familial neonatal-infantile epilepsy and early infantile developmental and epileptic encephalopathy.

Acta neuropathologica communications2026 Feb 25
#4

Rapid Electroclinical Evolution in HECW2-Related Developmental and Epileptic Encephalopathy: Report of a Likely Splicing Variant With Familial Transmission.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience2025 Aug

The HECW2 gene, essential for neurodevelopment, plays a critical role in maintaining cellular homeostasis and regulating key pathways in the nervous system. Deleterious variants in the HECW2 gene have been associated with developmental delay, intellectual disability, hypotonia and epilepsy, as well as dysmorphic features. We present the case of an infant with a novel variant in HECW2 with an unusual clinical presentation and a progressive disease course, showing three successive electroclinical patterns, consisting of burst suppression characteristic of early infantile developmental and epileptic encephalopathy, subcontinuous myoclonic seizures and infantile epileptic spasms syndrome without hypsarrhythmia, occurring over a short period of time. This case expands the clinical spectrum associated with this gene and highlights the intrafamilial phenotypic variability. It also underscores the importance of personalized therapeutic strategies, as demonstrated by the use of perampanel in this patient. These findings emphasize the need to include HECW2 as a possible aetiology in the diagnostic evaluation of developmental and epileptic encephalopathies.

#5

Nav1.2 channel mutations preventing fast inactivation lead to SCN2A encephalopathy.

Brain : a journal of neurology2025 Jan 07

SCN2A gene-related early-infantile developmental and epileptic encephalopathy (EI-DEE) is a rare and severe disorder that manifests in early infancy. SCN2A mutations affecting the fast inactivation gating mechanism can result in altered voltage dependence and incomplete inactivation of the encoded neuronal Nav1.2 channel and lead to abnormal neuronal excitability. In this study, we evaluated clinical data of seven missense Nav1.2 variants associated with DEE and performed molecular dynamics simulations, patch-clamp electrophysiology and dynamic clamp real-time neuronal modelling to elucidate the molecular and neuron-scale phenotypic consequences of the mutations. The N1662D mutation almost completely prevented fast inactivation without affecting activation. The comparison of wild-type and N1662D channel structures suggested that the ambifunctional hydrogen bond formation between residues N1662 and Q1494 is essential for fast inactivation. Fast inactivation could also be prevented with engineered Q1494A or Q1494L Nav1.2 channel variants, whereas Q1494E or Q149K variants resulted in incomplete inactivation and persistent current. Molecular dynamics simulations revealed a reduced affinity of the hydrophobic IFM-motif to its receptor site with N1662D and Q1494L variants relative to wild-type. These results demonstrate that the interactions between N1662 and Q1494 underpin the stability and the orientation of the inactivation gate and are essential for the development of fast inactivation. Six DEE-associated Nav1.2 variants, with mutations mapped to channel segments known to be implicated in fast inactivation were also evaluated. Remarkably, the L1657P variant also prevented fast inactivation and produced biophysical characteristics that were similar to those of N1662D, whereas the M1501V, M1501T, F1651C, P1658S and A1659V variants resulted in biophysical properties that were consistent with gain-of-function and enhanced action potential firing of hybrid neurons in dynamic action potential clamp experiments. Paradoxically, low densities of N1662D or L1657P currents potentiated action potential firing, whereas increased densities resulted in sustained depolarization. Our results provide novel structural insights into the molecular mechanism of Nav1.2 channel fast inactivation and inform treatment strategies for SCN2A-related EI-DEE. The contribution of non-inactivating Nav1.2 channels to neuronal excitability may constitute a distinct cellular mechanism in the pathogenesis of SCN2A-related DEE.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC6 artigos no totalmostrando 30

2026

Kcnq2 R213 knock-in mice reveal variant- and region-specific mechanisms underlying self-limited familial neonatal-infantile epilepsy and early infantile developmental and epileptic encephalopathy.

Acta neuropathologica communications
2026

Functional Characterization of a De Novo SCN2A Mixed Variant Linked to Early Infantile Developmental and Epileptic Encephalopathy.

Neurology. Genetics
2026

Long-Read Genome Sequencing Establishes Biallelic Pathogenic Variants in DNM1 With Distinct Functional Effects as the Cause of Early Infantile Developmental and Epileptic Encephalopathy.

American journal of medical genetics. Part A
2025

Genetic Etiology of Developmental and Epileptic Encephalopathy in a Turkish Cohort: A Single-Center Study with Targeted Gene Panel and Whole Exome Sequencing.

Genes
2025

Rapid Electroclinical Evolution in HECW2-Related Developmental and Epileptic Encephalopathy: Report of a Likely Splicing Variant With Familial Transmission.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2025

SCN1A gain of function effects in Dravet syndrome: Insights into clinical phenotypes and therapeutic implications.

Epilepsia open
2025

GABRA2-related encephalopathy: Identification of two phenotypes with distinctive electroclinical features.

Epilepsia
2024

Bilateral pulvinar responsive neurostimulation for bilateral multifocal posteriorly dominant drug resistant epilepsy.

Epilepsia open
2024

Voltage-gated sodium channel epilepsies in a tertiary care center: Phenotypic spectrum with correlation to predicted functional effects.

Epilepsy &amp; behavior : E&amp;B
2025

Nav1.2 channel mutations preventing fast inactivation lead to SCN2A encephalopathy.

Brain : a journal of neurology
2024

A retrospective study of the yield of next-generation sequencing in the diagnosis of developmental and epileptic encephalopathies and epileptic encephalopathies in 0-12 years aged children at a single tertiary care hospital in South India.

Epileptic disorders : international epilepsy journal with videotape
2024

Population-based study of rare epilepsy incidence in a US urban population.

Epilepsia
2024

Early onset epileptic and developmental encephalopathy and MOGS variants: a new diagnosis in the whole exome sequencing (WES) ERA : Report of a new patient and review of the literature.

Neurogenetics
2024

Late infantile epileptic encephalopathy: A distinct developmental and epileptic encephalopathy syndrome.

Epileptic disorders : international epilepsy journal with videotape
2023

Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes-a prospective observational study.

Brain communications
2023

Efficacy and tolerability of oxcarbazepine in the treatment of focal epilepsy in neonates and infants under 3 months of age: A single-center retrospective analysis.

Epilepsy research
2024

Use of ketogenic dietary therapy for drug-resistant epilepsy in early infancy.

Epilepsia open
2023

GABRA1-Related Disorders: From Genetic to Functional Pathways.

Annals of neurology
2023

Use of Sodium Channel Blockers in the Thr226Met Pathologic Variant of SCN1A: A Case Report.

Neuropediatrics
2023

Neonatal developmental and epileptic encephalopathy with movement disorders and arthrogryposis: A case report with a novel missense variant of SCN1A.

Brain &amp; development
2023

Long-Term Outcome of Neonatal Seizure with PACS2 Mutation: Case Series and Literature Review.

Children (Basel, Switzerland)
2023

EEG and clinical characteristics of neonatal parechovirus encephalitis.

Epilepsy research
2024

Biallelic variants of KCNQ2 in early infantile developmental and epileptic encephalopathy.

Seizure
2024

Cannabidiol Add-On in Glycosylphosphatidylinositol-Related Drug-Resistant Epilepsy.

Cannabis and cannabinoid research
2023

WWOX developmental and epileptic encephalopathy: Understanding the epileptology and the mortality risk.

Epilepsia
2022

Effects of the ketogenic diet therapy in patients with STXBP1-related encephalopathy.

Epilepsy research
2022

The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications.

Brain : a journal of neurology
2019

SCN1B-linked early infantile developmental and epileptic encephalopathy.

Annals of clinical and translational neurology
2018

A NGS-Targeted Autism/ID Panel Reveals Compound Heterozygous GNB5 Variants in a Novel Patient.

Frontiers in genetics
2018

PEHO syndrome: the endpoint of different genetic epilepsies.

Journal of medical genetics

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Encefalopatia epiléptica e do desenvolvimento infantil precoce.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Encefalopatia epiléptica e do desenvolvimento infantil precoce

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Functional Characterization of a De Novo SCN2A Mixed Variant Linked to Early Infantile Developmental and Epileptic Encephalopathy.
    Neurology. Genetics· 2026· PMID 41630925mais citado
  2. Long-Read Genome Sequencing Establishes Biallelic Pathogenic Variants in DNM1 With Distinct Functional Effects as the Cause of Early Infantile Developmental and Epileptic Encephalopathy.
    American journal of medical genetics. Part A· 2026· PMID 41340537mais citado
  3. Kcnq2 R213 knock-in mice reveal variant- and region-specific mechanisms underlying self-limited familial neonatal-infantile epilepsy and early infantile developmental and epileptic encephalopathy.
    Acta neuropathologica communications· 2026· PMID 41742307mais citado
  4. Rapid Electroclinical Evolution in HECW2-Related Developmental and Epileptic Encephalopathy: Report of a Likely Splicing Variant With Familial Transmission.
    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience· 2025· PMID 40879666mais citado
  5. Nav1.2 channel mutations preventing fast inactivation lead to SCN2A encephalopathy.
    Brain : a journal of neurology· 2025· PMID 38939966mais citado
  6. Genetic Etiology of Developmental and Epileptic Encephalopathy in a Turkish Cohort: A Single-Center Study with Targeted Gene Panel and Whole Exome Sequencing.
    Genes (Basel)· 2025· PMID 41153369recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:1934(Orphanet)
  2. MONDO:0800491(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Q55790899(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Encefalopatia epiléptica e do desenvolvimento infantil precoce

ORPHA:1934 · MONDO:0800491
Prevalência
Unknown
Herança
Autosomal dominant, Autosomal recessive, Not applicable, X-linked recessive
CID-10
G40.3 · Epilepsia e síndromes epilépticas generalizadas idiopáticas
CID-11
Início
Neonatal
Prevalência
0.0 (Europe)
MedGen
UMLS
C4479236
EuropePMC
Wikidata
Papers 10a
Evidência
🥇 Rev. sistemática
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades